Tirzepatide before and after: what real trial data tells you

Three months in: the picture most people don't expect

You've been on tirzepatide for twelve weeks. If your prescriber followed the standard titration schedule, you've probably just moved to the 7.5mg dose or are approaching it. Most people at this point have lost somewhere between 5% and 10% of their starting weight, meaningful, measurable, but not the dramatic transformation the internet's before-and-after photos often lead people to expect at the three-month mark.

That gap between expectation and reality has a straightforward explanation. The first pen (2.5mg for four weeks) is there to let your digestive system adjust. Nausea and other gastrointestinal effects are most common when the dose changes, and starting gently reduces the chance you'll need to pause or step back down. Weight loss during this phase is typically modest. The therapeutic work comes later, once you're established at a dose your body has settled into.

If you want a clearer sense of what those early weeks tend to look like, our detailed one-month tirzepatide results page walks through what's realistic at that stage specifically. For the three-month picture, including how to read the scales (water, muscle, fat loss differ), see our three-month results guide.

The honest message: the timeline is slower than social media makes it look, and that's fine. Slower loss at a therapeutic dose tends to be more durable.

What SURMOUNT-1 actually found, and what it didn't measure

SURMOUNT-1 is the trial most cited when people ask about tirzepatide weight-loss results. Published in the New England Journal of Medicine, it randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide at 5mg, 10mg, or 15mg, or to placebo, over 72 weeks. Average weight loss at the 15mg dose was around 20–21% of body weight, roughly 22kg for someone starting at 110kg. Around 90% of participants at the highest dose lost at least 5% of their body weight, and around half lost 20% or more.

Those are group averages. Individual results in the trial ranged considerably, and the people who lost the most tended to be those who combined treatment with meaningful changes to diet and activity, exactly what the licence requires. Tirzepatide is approved alongside a reduced-calorie diet and increased physical activity, not instead of them.

The trial also ran for 72 weeks, which matters. Many of the most striking before-and-after changes occurred between months four and twelve, not in the first two or three. This is worth keeping in mind when reading social-media accounts that show dramatic results very early, they may be genuine, but they're not the median experience.

NICE reviewed this evidence in detail when appraising tirzepatide (see NICE technology appraisal TA1026), and the trial data underpins its recommendation for use in adults who meet the eligibility criteria.

Changes beyond the scale: what before-and-after really captures

Weight in kilograms is the metric most people track, but it doesn't capture everything that changes. People in the SURMOUNT programme reported improvements in waist circumference, blood pressure, cholesterol levels, and markers of blood-sugar regulation, changes that don't photograph easily but matter enormously for long-term health. Some participants noticed shifts in how they thought about food, too: a reduction in the persistent background noise of hunger that had made previous attempts at losing weight so difficult.

Changes to the face are a question our prescribers hear fairly often. Fat loss doesn't happen uniformly, and some people notice facial changes before they see much difference elsewhere. Our guide to tirzepatide and facial changes covers what the evidence shows and what's normal to expect.

Results can also look different across sexes. If you'd like to understand how trial results and real-world patterns differ for men specifically, the tirzepatide results for men page goes into that in more detail.

One practical note: many people find it helpful to take a photo and measurements on the morning of their first dose, before the kettle's even on. The scale alone misses changes in body composition, so tracking multiple markers from the start gives a more accurate picture of progress over time.

How tirzepatide compares, and what shapes your own result

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg (Wegovy) in adults with obesity over 72 weeks. Tirzepatide produced greater average weight reduction. This is the only head-to-head trial between these two licensed medicines, and NICE's appraisal of tirzepatide referenced indirect comparisons that pointed in the same direction.

That said, which medicine produces better results for a specific person is something a prescriber works through, not something a comparison table settles. Tolerability, other health conditions, existing medications and personal preference all play a role. Our broader GLP-1 before-and-after page compares the licensed options in more detail.

On cost: tirzepatide is a private prescription medicine, and pricing varies between providers. If you're weighing up the financial side alongside what to expect from results, our Mounjaro cost guide explains what's included in a legitimate private prescription and what to watch out for. The Mounjaro timeline page also covers when most people start noticing a difference, week by week.

If you're ready to find out whether tirzepatide is clinically suitable for you, you can start a free consultation with our prescribers, reviewed the same day by a real clinician, not software.